MEI Pharma. has filed a patent for compositions, methods, and kits to treat cancer using a combination of a mitochondrial inhibitor and a Bcl-2 inhibitor. The patent claims a method of treating cancer by administering a Bcl-2 family inhibitor and a compound of formula (II) or a pharmaceutically acceptable salt thereof to a subject in need. GlobalData’s report on MEI Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MEI Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. MEI Pharma's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
A cancer treatment method using mitochondrial and bcl-2 inhibitors
A recently filed patent (Publication Number: US20230233519A1) describes a method of treating cancer by administering a Bcl-2 family inhibitor and a compound of formula (II) or a pharmaceutically acceptable salt thereof. The method involves administering these compounds to a subject in need of treatment. The patent claims specify various variations of the method, including different substitutions for R1, R2, R3, R4, R5, R6, R7, and R9 in the compound of formula (II). The patent also claims that the Bcl-2 family inhibitor can be an inhibitor of Bcl-2, Bcl-xL, Bcl-x, Bcl-w, Bcl-b, BH3-only, or MCL-1, and provides specific examples of Bcl-2 family inhibitors such as venetoclax, navitoclax, obatoclax mesylate, ABT-737, APG 2575, APG 1252, or AT-101.
The patent further specifies that the method can be used to treat various types of cancer, including leukemia, lymphoma, lung cancer, and hematological malignancies. Specific subtypes of leukemia mentioned in the claims include acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). For lung cancer, the patent mentions non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), lung carcinoid tumors, and adenoid cystic carcinoma as potential targets.
The claims also cover the administration of the Bcl-2 family inhibitor and compound of formula (II) either simultaneously or sequentially. Additionally, the patent describes the use of these compounds in pharmaceutical compositions and kits for the treatment of cancer. The compound of formula (II) or a pharmaceutically acceptable salt thereof is claimed for use in the treatment of cancer, leukemia, lymphoma, lung cancer, and hematological malignancies. Specific uses mentioned include the treatment of relapsed or refractory acute myeloid leukemia (AML) and AML that is resistant to standard of care therapy.
Overall, this patent describes a method of treating cancer using a combination of a Bcl-2 family inhibitor and a compound of formula (II) or a pharmaceutically acceptable salt thereof. The claims cover various substitutions in the compound of formula (II), different types of cancer that can be treated, and the use of these compounds in pharmaceutical compositions and kits.
To know more about GlobalData’s detailed insights on MEI Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
